Τόμος 17 (2003) – Τεύχος 3 – Άρθρο 4 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 17 (2003) – Issue 3 – Article 4 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Technological Educational Institution of Athens, Egaleo, Athens, Greece

 Accepted for publication: 1 October 2003

pharmakonpress[at]pharmakonpress[.]gr

2.    Grimes P.E., Stockton T.: Pigmentary disorders in blacks. Dermatol. Clin. 6: 271-281 (1988)

3.    Deltsidou A., Lykeridou K., Plessas S.: Congenital anomalies and aetiology. Rev. Clin. Pharmacol. Pharmaco-kinet. (Intern. Ed.) 14: 111-115 (2000)

4.    Δελτσίδου A., Λυκερίδου K., Πλέσσας Σ.: Μεταφορά φαρμάκων δια μέσου του πλακούντα. Επιθ. Κλιν. Φαρμακ. Φαρμακοκ. 18: 173-180 (2000)

5.    Deltsidou A., Lykeridou K., Plessas S.: Licit substance abuse during pregnancy and its effects on the fetus. Rev. Clin. Pharmacol. Pharmacokinet. (Intern. Ed.) 15: 21-32 (2001)

6.    Grimes P.: Melasma. Etiology and Therapeutic considerations. Arch. Dermatol. 113: 1453-1457 (1995)

7.    Kefala V., Kostara I., Karageorgiou H., Varonos D.D.: In Vitro model for the Evaluation of Sunscreen Agents Phototoxic Activity. Rev. Clin. Pharmacol. Pharmacokin. (Intern. Ed.) 12: 59-62 (1998)

8.    Κίντζιου E., Πρωτόπαπα E., Τσαγανέας Χ.Π., Σταυριανέας N., Πλέσσα E.: Ηλιακή Ακτινοβολία, Βλάβη DNA και Καρκίνος Δέρματος: Σύντομη Θεώρηση. Επιθ. Κλιν. Φαρμακολ. Φαρμακοκιν. 20: 42-52 (2002)

9.    Kefala V., Kostara l., Karageorgiou Η., Varonos D.D.: In Vitro Model for the Evaluation of Preservatives Phototoxic Activity. Rev. Clin. Pharmacol. Pharmacokinet. (Intern. Ed.) 14: 93-96 (2000)

10.  Kefala V., Kostara l., Karageorgiou H., Varonos D.D.: In Vitro Model for the Evaluation of Essential Oils Materials Phototoxic Activity. Rev. Clinical. Pharmacol. Pharmacokinet. (Intern. Ed.) 12: 53-57 (1998)

11.  Kefala V., Kostara l., Karageorgiou H., Varonos D.D.: in Vitro Model for the Evaluation of Medicines Phototoxic Activity. Rev. Clinical. Pharmacol. Pharmacokinet. (Intern. Ed.) 14: 43-47 (2000)

12.  Kefala V., Protopapa E., Plessas S.T.: Photoaging: An Esthetic Problem: Prevention or Treatment? Rev. Clin. Pharmacol. Pharmacokinet. (Intern. Ed.) 15: 33-42 (2001)

13.  Katsambas A., Antoniou C.: Melasma – Classification and treatment. J. Eur. Acad. Dermatol. Venerol. 4: 217-223 (1995)

14.  Mishima Y., Hatta S., Ohyama Y., Inazu M.: Induction of melanogenesis suppression: cellular pharmacology and mode of differential action. Pigment. Cell. Res. 1: 367-374 (1998)

15.  Lykeridou K., Deltsidou A.: Epidural analgesia during normal labor. Epitheor. Klin. Farmacol. Farmakokinet. (Intern. Ed.) 16: 183-198 (2002)

16.  Sanchez J.L., Vazquez M.: A hydroquinone solution in the treatment of melasma. Int. J. Dermatol. 21: 55-58 (1982).

17.  Yi K., Hart L.L.: Use of hydroquinone as a bleaching cream. Ann. Pharmacother. 27: 592-593 (1993)

18.  Engasser P.E., Maibach H.J.: Cosmetics and dermatology: bleaching creams. J. Am. Acad. Dermatol. 5: 143-147 (1981)

19.  Kefala V., Kinigalaki P.: In vitro evaluation of the effect of b-cyclodextrin on sebum secretion in people developing two kinds of acne vulgaris: A. Comedonal acne and B. Cosmetic acne. Rev. Clin. Pharmacol. Pharmacokinet. (Intern. Ed.) 16: 179-182 (2002)

20.  Kameyama K., et al.: Inhibitory effect of magnesium L-ascocbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J. Am. Acad. Dermatol. 34: 29-33 (1996)

21.  Lim J. T., Tham S.N.: Clycolic acid peels in the treatment of melasma among Asian women. Dermatol. Surg. 23: 177-179(1997)

22.  Kanwar A.J., Dhar S., Kaur S.: Treatment of melasma with potent topical corticosteroids. Dermatol. 188: 170-175 (1994)

23.  Griffiths C.E., Finkel L.T., Ditre C.M., Hamilton T.A., Ellis C.N., Voorhees J.J.: Topical tretinoin improves melasma: a vehicle controlled, clinical trial. Br. J. Dermatol. 129: 415-421 (1993)

24.  Vashimura K., Harii K., Aoyama T., Shibuya F., Jga T.: A new bleaching protocol for hyperpigmented skin lesions with a high concentration of all-trans retinoic acid aqueous gel. Aesthetic. Plast. Surg. 23: 285-291 (1999)

25.  Baltina L.M., Craupe K.: The treatment of melasma: 20% ajelaic acid versus 4% hydroquinone cream. Int. J. Dermatol. 30: 893-895 (1991)

26.  Breathnach A.S.: Melanin hyperpigmentation of skin: Melasma topical treatment with azelaic acid and other therapies. Cutis 57: 36-39 (1996)

27.  Verallo-Rowell V.M. et al.: Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta. Derm. Venereol. 143(Suppl.): 58-61 (1989)

28.  Njoo M.D., Menke H.E., Pavel S., Westechof W.: N-acetylcystein as a bleaching agent in the treatment of melasma. J. Eur. Acad. Dermatol. Venereol. 9: 86-87 (1997)

29.  Jimbow K.: N-acetyl-4-S-cystemrnylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch. Dermatol. 127: 1528-1534 (1991)

30.  Lim J.T.: Treatment of melasma using Kojic acid in gel containing hydroquinone and glycolic acid. Dermatol. Surg. 25: 282-284 (1999)

31.  Carcia A., Fulton J.E.: The combination of glycolic acid and hydroquinone or Kojic acid for the treatment of melasma and related conditions. Dermatol. Surg. 22: 443- 447(1996)

32.  Kahn V.: Effect of Kojic acid on the oxidation of DL-DOPA, norepinephrine, and dopanine by mooshroom tyrosinase. Pigment. Cell. Res. 6: 234-240(1995)

33.  Guevara I.L., Pandya A.G.: Melasma treated with hydroquinone, tretinoin and a fluorinated steroid. Int. J. Dermatol. 40(3): 212-215 (2001)

34.  Kang N.H., Chun S.C., Lee S.: Intermittent therapy for melasma in Asian patients with combined topical agents (retinoin acid, hydroquinone and hydrocortisone): clinical and histological studies. J. Dermatol. 25: 587-596 (1998)

35.  Kefala V., Protopapa E., Plessas S.T.: The use of chemical peeling in the management of esthetic problems deriving from skin diseases. Rev. Clin. Pharmacol. Pharmacokinet. (Intern. Ed.) 15: 5-14 (2001)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr